DEUTSCHE BANK AG\ - PROQR THRAPEUTICS N V ownership

PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 50 filers reported holding PROQR THRAPEUTICS N V in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of PROQR THRAPEUTICS N V
ValueSharesWeighting
Q2 2023$624,037
-23.9%
385,2080.0%0.00%
Q1 2023$820,493
-42.4%
385,2080.0%0.00%
-100.0%
Q4 2022$1,425,270
+396.6%
385,2080.0%0.00%
Q3 2022$287,000
-4.3%
385,2080.0%0.00%
Q2 2022$300,000
-14.0%
385,2080.0%0.00%
Q1 2022$349,000
-91.4%
385,208
-24.0%
0.00%
-100.0%
Q4 2021$4,058,000
-16.5%
506,618
-12.8%
0.00%0.0%
Q3 2021$4,861,000
+24.0%
580,802
-0.1%
0.00%0.0%
Q2 2021$3,920,000
-15.9%
581,499
-17.5%
0.00%
-33.3%
Q1 2021$4,659,000
+513.0%
704,880
+289.6%
0.00%
Q4 2020$760,000
+2011.1%
180,927
+4863.7%
0.00%
Q4 2019$36,000
-83.4%
3,645
-90.4%
0.00%
Q3 2019$217,000
+36.5%
37,983
+114.4%
0.00%
Q2 2019$159,000
-45.7%
17,715
-16.7%
0.00%
Q1 2019$293,000
+113.9%
21,261
+142.3%
0.00%
Q4 2018$137,000
+197.8%
8,773
-7.7%
0.00%
Q3 2017$46,000
+411.1%
9,500
+556.5%
0.00%
Q3 2016$9,000
-87.3%
1,447
-90.3%
0.00%
Q2 2016$71,000
+688.9%
14,907
+645.4%
0.00%
Q1 2016$9,000
-93.2%
2,000
-87.0%
0.00%
Q4 2015$132,000
+388.9%
15,336
+707.2%
0.00%
Q3 2015$27,000
-93.5%
1,900
-92.4%
0.00%
Q2 2015$418,000
-17.1%
25,141
+9.0%
0.00%
Q1 2015$504,000
+105.7%
23,058
+103.7%
0.00%
Q4 2014$245,000
-41.0%
11,318
-53.1%
0.00%
Q3 2014$415,00024,1480.00%
Other shareholders
PROQR THRAPEUTICS N V shareholders Q3 2022
NameSharesValueWeighting ↓
M28 Capital Management LP 1,910,600$3,095,1724.09%
Privium Fund Management B.V. 5,344,446$8,658,0031.82%
DAFNA Capital Management LLC 940,582$1,523,7430.42%
Opaleye Management Inc. 653,000$1,057,8600.25%
Ikarian Capital, LLC 472,625$765,6530.12%
EcoR1 Capital, LLC 2,980,016$4,827,6260.12%
Monaco Asset Management SAM 237,517$384,7780.11%
FRANKLIN STREET ADVISORS INC /NC 150,000$2430.02%
ADAGE CAPITAL PARTNERS GP, L.L.C. 3,625,467$5,873,2570.01%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 189,328$306,7110.01%
View complete list of PROQR THRAPEUTICS N V shareholders